Diabetes Archives -

FDA backs Glenmark’s rival to AZ’s blockbuster Farxiga

https://pharmaphorum.com/news/fda-tentatively-backs-glenmarks-farxiga-generic/

Could GLP-1 drugs treat space headaches? NASA wants to know.

https://pharmaphorum.com/news/nasa-looks-on-as-uk-researchers-test-glp-1-drugs-against-space-headaches/

3rd Chronic Kidney Disease Drug Development (CKD3) Summit

https://pharmaphorum.com/events/3rd-chronic-kidney-disease-drug-development-ckd3-summit/

FDA approves MACE label claim for Lilly’s Trulicity

https://pharmaphorum.com/news/fda-approves-mace-label-claim-for-lillys-trulicity/

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

https://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/

Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nod

https://pharmaphorum.com/news/novo-nordisk-nears-eu-okay-for-oral-semaglutide-after-chmp-nod/

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

https://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/

Livongo looks to set itself apart from digital health rivals

https://pharmaphorum.com/views-analysis-digital/livongo-looks-to-set-itself-apart-from-digital-health-rivals/

Novo’s Ozempic gains MACE risk reduction label in US

https://pharmaphorum.com/news/novos-ozempic-gains-mace-risk-reduction-label-in-us/

Search